← Back to Clinical Trials
Recruiting NCT06387017

Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway

Trial Parameters

Condition Smoking-related Pathology
Sponsor Assistance Publique Hopitaux De Marseille
Study Type INTERVENTIONAL
Phase N/A
Enrollment 750
Sex ALL
Min Age 45 Years
Max Age 80 Years
Start Date 2024-04-02
Completion 2028-07
Interventions
blood samplingstool collectionlow dose CT scan

Brief Summary

Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood profile and of the microbiota; systematic proposal of smoking cessation for active smokers or assistance in maintaining cessation.

Eligibility Criteria

Inclusion Criteria: * 1- All PREVALUNG or PREVALUNG ETOILE participants * 2- Active or former smokers who have smoked daily for at least 10 years and have either atheromatous disease (coronary, lower limb, supra-aortic trunk, aortic, visceral or upper limb arteries) or a moderate or high coronary calcium score\*, \*\*. Inclusion criteria: * Age 45- 75 years and * Medical follow-up for smoking-related atheromatous pathology and * daily smoking for at least 10 years prior to disease (for smoking, there are no quantitative criteria or withdrawal times) * visual coronary calcium score quantified by a radiologist on a chest CT scan. 3- Individuals at risk of lung cancer without atheromatous disease or moderate or high calcium score being managed for a tobacco-related disease (chronic bronchitis or non-progressive cancer \> 5 years) or with eligibility criteria for lung cancer screening (inclusion criteria in the NLST or NELSON studies or American recommendations)\*\*. Inclusion criteria : *

Related Trials